证券记录 · 已归档季度
BMY
Bristol-Myers Squibb Company · Healthcare · Drug Manufacturers - General
19被追踪持有人
n/aΔ持有人
159.17M持有股份
$6.60B报告持仓市值
+0新建仓位
−0清仓
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q2 2024
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 2.35M | $122.19M | n/a | n/a |
| Q2 2026 | 172 | +1 | 1.32B | $76.14B | +6 | −6 |
| Q1 2026 | 175 | +1 | 1.27B | $76.90B | +4 | −4 |
| Q4 2025 | 173 | +1 | 1.36B | $73.29B | +2 | n/a |
| Q3 2025 | 26 | 0 | 840.35M | $37.89B | n/a | −1 |
| Q2 2025 | 24 | +1 | 649.62M | $30.06B | +2 | −1 |
| Q1 2025 | 20 | 0 | 256.22M | $15.62B | +1 | −1 |
| Q4 2024 | 20 | -1 | 253.42M | $14.33B | n/a | −1 |
| Q3 2024 | 20 | +1 | 169.93M | $8.78B | +1 | n/a |
| Q2 2024 | 19 | n/a | 159.17M | $6.60B | n/a | n/a |
持有人 · Q2 2024
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (被动) | 42.17M | n/a | $1.75B | 0.2% | n/c | 1 | SEC ↗ ×2 |
| 2 | Norges Bank ✦ (被动) | 32.59M | n/a | $1.35B | 0.2% | n/c | 1 | SEC ↗ |
| 3 | PRIMECAP Management ✦ | 23.50M | n/a | $975.90M | 0.7% | n/c | 1 | SEC ↗ |
| 4 | Dodge & Cox ✦ | 15.77M | n/a | $654.80M | 0.4% | n/c | 1 | SEC ↗ |
| 5 | T. Rowe Price ✦ | 15.30M | n/a | $635.43M | 0.1% | n/c | 1 | SEC ↗ ×2 |
| 6 | Citadel Advisors ✦ | 11.01M | n/a | $455.66M | 0.5% | n/c | 1 | SEC ↗ ×3 |
| 7 | Two Sigma Investments ✦ | 6.17M | n/a | $256.44M | 0.6% | n/c | 1 | SEC ↗ |
| 8 | Arrowstreet Capital ✦ | 2.92M | n/a | $121.25M | 0.1% | n/c | 1 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 2.68M | n/a | $111.15M | 0.2% | n/c | 1 | SEC ↗ ×5 |
| 10 | D. E. Shaw & Co. ✦ | 2.45M | n/a | $101.92M | 0.2% | n/c | 1 | SEC ↗ ×2 |
| 11 | Millennium Management ✦ | 1.49M | n/a | $61.91M | 0.1% | n/c | 1 | SEC ↗ |
| 12 | Adage Capital Partners ✦ | 871.63K | n/a | $36.20M | 0.1% | n/c | 1 | SEC ↗ |
| 13 | Point72 Asset Management ✦ | 637.99K | n/a | $26.50M | 0.1% | n/c | 1 | SEC ↗ |
| 14 | Bridgewater Associates ✦ | 554.99K | n/a | $23.05M | 0.1% | n/c | 1 | SEC ↗ |
| 15 | Gotham Asset Management ✦ | 286.84K | n/a | $11.91M | 0.2% | n/c | 1 | SEC ↗ |
| 16 | Marshall Wace ✦ | 255.73K | n/a | $10.62M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 17 | Fisher Asset Management ✦ | 228.00K | n/a | $9.47M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | Wellington Management ✦ | 166.71K | n/a | $6.92M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 19 | GAMCO Investors ✦ | 111.44K | n/a | $4.63M | 0.1% | n/c | 1 | SEC ↗ |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例，即持仓信心指标。✦ = 精选管理人。
新增买入方
| 本季度无新增被追踪买入方。 |
已清仓
| 本季度无被追踪的退出仓位。 |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 1 持有人, 6.60K 股份, $400 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
持有该证券的受追踪机构最常同时持有的其他证券：基于共同持有计数，而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Sep 09
Massacesi Cristian
Officer · 6.25K 股 · $403,498
Aug 25
Holzer Phil M
Officer · 500 股 · $33,750
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论
Aug 07
SC 13G: STATE STREET CORP
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q2 2024 ·
方法论 ·
通过API获取此数据